Quality of Life Associated with Nausea and Vomiting from Anthracycline-Based Chemotherapy: A Pooled Data Analysis from Three Prospective Trials

CONCLUSION: CINV had a significant impact on the QoL of breast cancer patients treated with AC over multiple cycles. IMPLICATIONS FOR PRACTICE: This is a post-hoc analysis of 3 prospective studies for the control of chemotherapy-induced nausea and vomiting (CINV); quality of life (QoL) using contemporary antiemetic regimens in a homogenous group of Chinese breast cancer patients who were receiving a uniform (neo)adjuvant chemotherapy regimen of doxorubicin and cyclophosphamide were evaluated. The results reveal that QoL (based on mean scores for the FLIE) were significantly better for patients who did not experience vomiting or significant nausea than those who did during the first as well as subsequent cycles of chemotherapy. In addition, QoL in an earlier cycle affected the QOL in subsequent cycles of AC. Further, more recent regimens involving olanzapine/aprepitant or NEPA was also associated with a positive impact in patients' quality of life. Antiemetic guideline-consistent practice and higher clinician awareness of the impact of CINV on patients QoL can further mitigate the negative effects of CINV on patients QoL.PMID:34516038 | DOI:10.1002/onco.13978
Source: The Oncologist - Category: Cancer & Oncology Authors: Source Type: research